Recruiting

Remote Monitoring

Sponsor:

UCLA

Code:

NCT07673237

Conditions

Fibrotic Interstitial Lung Disease

IPF and PPF

Lung Fibrosis Interstitial

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Spirometer

Oximeter

Scale

ePROs (electronic patient reported outcomes)

Study Details

Brief summary:

The purpose of this interventional study is to identify which combination of remote monitoring devices (e.g. home spirometry, pulse oximetry, scale, ePROs) is the most feasible (as defined by adherence, retention, and data completeness) and acceptable when used for the detection of clinically significant Interstitial Lung Disease events.

Conditions

Fibrotic Interstitial Lung Disease

IPF and PPF

Lung Fibrosis Interstitial

Study ID

NCT07673237

Start date

Oct 1, 2026

Status verified date

Sep, 2026

Completion date

Aug 1, 2028

Anticipated

Primary completion date

Aug 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • age 18 or older
  • English or Spanish speaking
  • have a UCSF diagnosis of one of the major ILD subtypes seen in the ILD Clinic (Idiopathic Pulmonary Fibrosis, Chronic Hypersensitivity Pneumonitis, Connective-tissue disease related ILD, Sarcoidosis, Familial Fibrosis). Languages are limited to those for which both device instructional materials and user support are available (written and video). The ILD diagnosis will be based on multidisciplinary conference review, which is the diagnostic gold standard. We have restricted the ILD subtypes to those for which there is efficacy data for RPM or comparable clinical trajectories, and subtypes that account for >10% of the ILD diagnoses seen at UCSF.

Exclusion Criteria:

  • Patients who are unable provide informed consent for any reason or are acutely ill.

Study Design

Enrollment

200 participants

Anticipated

Allocation

Randomized

Intervention Model

Factorial

Primary purpose

Health Services Research

Interventions and Outcome Measures

Arms

experimental: Spirometry Only

Participants randomized to Arm 1 will perform home spirometry weekly by completing a spirometry maneuver (inhaling and exhaling through the device mouthpiece). Participants will also complete brief symptom questionnaires electronically throughout the study period.

experimental: Spirometer and Oximeter

Participants randomized to Arm 2 will perform home spirometry weekly by completing a spirometry maneuver (inhaling and exhaling through the device mouthpiece) and will measure oxygen saturation levels daily using a pulse oximeter. Participants will also complete brief electronic symptom questionnaires throughout the study period.

experimental: Spirometer and Scale (weight)

Participants randomized to Arm 3 will perform home spirometry weekly by completing a spirometry maneuver (inhaling and exhaling through the device mouthpiece) and will measure their weight weekly using the wireless scale provided by the study. Participants will also complete brief electronic symptom questionnaires throughout the study period.

experimental: Spirometer, Oximeter, and Scale (weight)

Participants randomized to Arm 4 will perform home spirometry weekly by completing a spirometry maneuver (inhaling and exhaling through the device mouthpiece), measure oxygen saturation levels daily using a pulse oximeter, and measure their weight weekly using the wireless scale provided by the study. Participants will also complete brief electronic symptom questionnaires throughout the study period.

Interventions

Spirometer

Home spirometry will be conducted weekly by completing a spirometry maneuver (inhaling and exhaling through the device mouthpiece).

Oximeter

Oxygen saturation levels will be measured daily using a pulse oximeter.

Scale

Weight will be measured weekly using a wireless scale provided by the study.

ePROs (electronic patient reported outcomes)

Brief electronic symptom questionnaires will be completed through a secure app which will be downloaded on participant's phone.

Primary outcome measure

  • Detection rate of clinically significant ILD events [ Time Frame: Baseline, Month 12 ]
  • Time to detection of first ILD event [ Time Frame: Baseline, Month 12 ]
  • Adherence [ Time Frame: 12 months ]
  • Retention [ Time Frame: 12 months ]
  • Data Completeness [ Time Frame: 12 months ]

Central Contacts and Locations

Central contacts

Erica D Farrand, MD

415-476-8067Erica.Farrand@ucsf.edu

Yeji Lee

415-353-9744Yeji.Lee@ucsf.edu

Locations

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94117

Contacts

Yeji Lee

415-353-9744Yeji.Lee@ucsf.edu

Principal Investigator:

Erica D Farrand, MD

More Information

Sponsor

University of California, San Francisco

Last update posted

Oct 5, 2026

Last verified

Sep, 2026

Keywords

  • Interstitial lung disease
  • pulmonary fibrosis
  • idiopathic pulmonary fibrosis
  • progressive pulmonary fibrosis
  • Remote patient monitoring
  • Digital health
  • Telemonitoring
  • Home monitoring
  • Pragmatic study design
  • Real-world monitoring
  • Decentralized clinical trial

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-06. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-10-05. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.